Codexis, Inc. (NASDAQ: CDXS) is a Healthcare company (Biotechnology) with a market capitalization of $117M. The Maz Rating grades it against the other companies in its sector.
Codexis, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.07, Codexis, Inc. trades at 1.3x sales and 2.2x book value. Over the last twelve months it generated about $90M of revenue and a net loss of $22M. It runs a gross margin of 83.9%, an operating margin of -14.4% and a net margin of -21.8%. It shows return on equity of -43.2%, return on invested capital of -10.2% and a free cash flow yield of -10.4%. On the balance sheet: a debt-to-equity ratio of 1.41 and a current ratio of 2.81. Over the past 52 weeks the share price ranged from $0.90 to $2.98, with a beta of 2.39.
Codexis, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 9 Buy and 5 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.